InsidersTradesSigma
Total declarations
Companies
▲ Purchases (4 ops.)
▼ Sales (0 ops.)
Discover the detailed record of transactions filed by SCHIMMEL PAUL, Director. Director active across 2 companies, notably aTYR PHARMA INC. Aggregated, 4 disclosures have been logged. Total volume traded: €3.7m. The latest transaction was filed on 20 September 2021 (Acquisition). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations4 total
€2m250,000 shares@ €6.82100.0% of flow
Common Stock
SEC:0001209191-21-057339·
Ideal exit: 17 Jun 2022 (T+270)
€2m250,000 shares@ €6.822.22% mcap84.0% of flow
Common Stock
SEC:0001209191-21-057339:0·
Ideal exit: 17 Jun 2022 (T+270)
€162,79550,000 shares@ €3.2559100.0% of flow
Common Stock
SEC:0001209191-21-034293·
Ideal exit: 12 Feb 2022 (T+270)
€162,79550,000 shares@ €3.25590.21% mcap8.0% of flow
Common Stock
SEC:0001209191-21-034293:0·
Ideal exit: 12 Feb 2022 (T+270)
4 of 4 declarations
About SCHIMMEL PAUL
Paul Schimmel is a Board Member at aTYR Pharma Inc. He plays a key role in the governance of the company, contributing to strategic decision-making and overseeing operations. His experience in the pharmaceutical sector allows him to provide valuable insights to the board.
